As the global population ages, the rising prevalence of neurodegenerative disorders and age-related cognitive impairment poses a significant challenge to ...
A new study shows how common gut bacteria can metabolize certain oral medications that target cellular receptors called GPCRs, potentially rendering these important drugs less effective. A new study, ...
New findings highlight correlations between EEG and clinical outcome measures in Alzheimer’s disease Cognito Therapeutics, a late clinical-stage neurotechnology company pioneering non-invasive ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--#alzheimers--Cognito Therapeutics, a late clinical-stage neurotechnology company pioneering non-invasive therapies for neurodegenerative diseases, today announced ...
Forbes contributors publish independent expert analyses and insights. I’m an analyst covering neurotech's impact on business and society. Cognito Therapeutics announced a $105 million Series C round ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A Cambridge company is on its ...
Cognito Therapeutics, a company using visual and auditory stimulation to treat neurodegenerative disorders, announced it closed an oversubscribed $105 million Series C funding round. Morningside ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, a late clinical-stage neurotechnology company pioneering non-invasive neuroprotective therapies in neurodegenerative diseases, today announced ...
Mario Aguilar covers technology in health care, including artificial intelligence, virtual reality, wearable devices, telehealth, and digital therapeutics. His stories explore how tech is changing the ...
The addition of a Lactobacillus probiotic supplement to the phytochemical-rich food supplement significantly improved rate of PSA progression from 23.2% to -21.4% (44.6% change, P 0.001), compared to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results